Pneumagen

Pneumagen

Pneumagen

Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.
Founded
2016
Raised
$5.1M
Follow us
Latest funding
£4,000,000
Venture capital - 2020
Scottish Investment Bank Thairm Bio
Team Size
1–10
Employees
£4,000,000 Venture capital
FinSMEs

Pneumagen Raises £4M in Funding